Uterine fibroids are non-cancerous growths of the muscle wall of the uterus. Doctors also call them leiomyomas or myomas. Some are as small as a pea; others grow as large as a cantaloupe. They are the most common tumor of the female reproductive tract.
Fibroids are very common. In a study that screened women aged 35 to 49 with ultrasound, the estimated share who develop fibroids by age 50 was more than 80% of Black women and nearly 70% of white women.1
Many fibroids cause no symptoms. Others cause heavy or painful periods, pressure and pain in the pelvis, trouble passing urine and a growing belly. The treatment often offered is hysterectomy, removal of the uterus. It is not the only one. Uterine fibroid embolization (UFE) blocks the blood supply of the fibroids so they shrink, and the uterus stays. Every woman should be given factual information so that she can make the best treatment decision for herself. Too often she is given misleading information about fibroids and about UFE instead.
Why it matters
The trouble fibroids cause is of two kinds: heavy bleeding, and the “bulk” symptoms of an enlarged uterus. Either can be severe.
Heavy bleeding. Heavy periods can cause anemia, a low blood count. At times the bleeding is severe enough to need blood transfusions and admission to hospital.
Bulk symptoms. A markedly enlarged uterus presses on the bladder and the bowel. The result is urgency and frequency in passing urine, getting up many times a night to pass urine, constipation, and a growing waistline.
Treatment
Uterine fibroid embolization. An artery is reached through a needle puncture in the groin or the wrist, under local anesthetic and intravenous sedation, with no general anesthetic. A thin tube (catheter) is guided on live X-ray to the arteries that feed the fibroids. Tiny particles are injected through it. They block the blood supply of the fibroids, which then shrink. UFE can be done as an outpatient procedure, with no overnight stay. Most women return to their usual activities within 1 to 2 weeks, depending on their recovery and general health.
A woman of 43 with fibroids pressing on her bladder had urinary frequency, nausea, bloating and pelvic discomfort. After UFE her uterus shrank and her symptoms improved markedly (the case).
After UFE, heavy bleeding settles, periods return to normal, pelvic pain and pressure ease, the need to pass urine often decreases, and the fibroids are significantly reduced in size. The uterus stays.
How it compares with surgery. In trials that compared UFE with hysterectomy or myomectomy (an operation that removes the fibroids and leaves the uterus), satisfaction was not clearly different after UFE than after surgery. They needed fewer blood transfusions, spent less time in hospital and returned to usual activities sooner. Major complications were no more common after UFE. Minor complications were more common, and so was further treatment: within two to five years more women needed another procedure after UFE than after surgery.2 In a trial of UFE against hysterectomy, about two thirds of the women treated with UFE still had not needed a hysterectomy ten years later, and their quality of life was as good as after hysterectomy.3
Who it suits. UFE suits women who want to keep the uterus, avoid an operation, or avoid an early menopause. Embolization is also very effective for the symptoms of adenomyosis, a related condition in which tissue like the lining of the uterus grows within its muscle wall.4
Clinical evaluation. The key to an effective treatment is the clinical evaluation at the consultation, which determines whether UFE is right for her. The treatments are not always alternatives. Sometimes the best result comes from combining them, with a myomectomy after UFE: for example a hysteroscopic myomectomy, in which a fibroid lying in the cavity of the uterus is removed through the cervix with a slim telescope, with no incision.
One of the big frustrations, for my patients and for me, is that too often women are not given all the options. If they are told about UFE at all, it is followed by “you’re not the right patient for it,” rather than having someone who does UFE see them. We do too many hysterectomies in this country, and not enough fibroid embolizations.
UFE is well studied, yet many women are never told about it. A study presented at the Society of Interventional Radiology’s 2017 annual meeting found more than 65 times as many hysterectomies for fibroids as embolizations in U.S. inpatient records from 2012–2013.5 UFE was especially underused in rural and smaller hospitals, although it resulted in substantially lower costs and shorter hospital stays than hysterectomy.5 The result is unnecessary hysterectomies and increased costs.
Robert Vogelzang, MD, of Northwestern University in Chicago, said in 2016 that UFE had still not achieved the use it should, despite two decades of experience, and that “sadly, the patients who have fibroids are often not being told about embolization.” By his estimate about 10% of fibroids in America were treated with UFE, which “still leaves hundreds of thousands of fibroids being treated by old means, which is unnecessary.”6
What women are told
UFE competes with myomectomy and hysterectomy for the treatment of fibroids. These are the common myths, each with the facts:
- “You may have a cancer so you need the fibroid removed.” Fewer than 1% of fibroids are malignant. In a pooled analysis of the published studies of women who had surgery for what were thought to be fibroids, about 3 in 1,000 (1 in 340) proved to have a uterine sarcoma, a rare cancer of the uterus.7 The estimated risk rises with age, from fewer than 1 in 500 in women under 30 to 1 in 98 in women aged 75 to 79.7 MRI can identify most of these cancers.8 Subjecting every woman to a hysterectomy because of this very small risk is not reasonable.
- “Sexual function [gets] worse.” The largest prospective study of sexual function after UFE showed excellent outcomes, with women’s sex lives improved: more than 90% of women reported a better quality of life a year later, and about 80% reported better sexual function, including less pain and greater desire, arousal and satisfaction.9
- “You have the wrong kind of fibroids.” The vast majority of fibroids can be treated with UFE.
- “Your fibroids are too large.” Size can affect how much the bulk symptoms improve: extremely large fibroids, more than 10 centimeters across, may not shrink enough.
- “You can’t get pregnant after UFE.” Pregnancy is achievable after UFE.10 In one study of 359 women with fibroids or adenomyosis who had been unable to conceive, 131 had a live birth after embolization.10 That study did not compare UFE with myomectomy. In the randomized FEMME trial, too few women became pregnant to tell which treatment gives a better chance of becoming pregnant.11
- “You will end up in menopause after UFE.” Only a very small percentage of women, typically those already close to menopause, go into menopause after UFE.
- “UFE pain is unbearable.” Pain after embolization can be easily managed, and the vast majority of women are treated as outpatients. Local anesthetic given into the arteries after embolization and a nerve block of the pelvic nerves (a superior hypogastric nerve block), used routinely, significantly decrease the pain.
References
- Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100–107. https://doi.org/10.1067/mob.2003.99
- Gupta JK, Sinha A, Lumsden MA, Hickey M. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2014;2014(12):CD005073. https://doi.org/10.1002/14651858.CD005073.pub4
- de Bruijn AM, Ankum WM, Reekers JA, et al. Uterine artery embolization vs hysterectomy in the treatment of symptomatic uterine fibroids: 10-year outcomes from the randomized EMMY trial. Am J Obstet Gynecol. 2016;215(6):745.e1–745.e12. https://doi.org/10.1016/j.ajog.2016.06.051
- Inì C, Timpanaro C, Foti PV, Tiralongo F, et al. Uterine artery embolization for the treatment of symptomatic adenomyosis: a systematic review. CVIR Endovasc. 2026;9(1):87. https://doi.org/10.1186/s42155-026-00727-2
- Narayanan S, Gonzalez A, Echenique A, Mohan P. Nationwide analysis of hospital characteristics, demographics, and cost of uterine fibroid embolization. J Vasc Interv Radiol. 2017;28(2):S48. https://doi.org/10.1016/j.jvir.2016.12.700
- French multicenter uterine fibroid embolization study shows improvements in sexual desire and function, quality of life. Endovascular Today. Published April 2, 2016. Accessed November 13, 2026. https://evtoday.com/news/french-multicenter-uterine-fibroid-embolization-study-shows-improvements-in-sexual-desire-and-function-quality-of-life
- Brohl AS, Li L, Andikyan V, et al. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015;20(4):433–439. https://doi.org/10.1634/theoncologist.2014-0361
- Abdel Wahab C, Jannot AS, Bonaffini PA, et al. Diagnostic algorithm to differentiate benign atypical leiomyomas from malignant uterine sarcomas with diffusion-weighted MRI. Radiology. 2020;297(2):361–371. https://doi.org/10.1148/radiol.2020191658
- Vernhet Kovacsik H, Herbreteau D, Bommart S, Beregi JP, et al. Evaluation of changes in sexual function related to uterine fibroid embolization (UFE): results of the EFUZEN study. Cardiovasc Intervent Radiol. 2017;40(8):1169–1175. https://doi.org/10.1007/s00270-017-1615-3
- Pisco JM, Duarte M, Bilhim T, et al. Spontaneous pregnancy with a live birth after conventional and partial uterine fibroid embolization. Radiology. 2017;285(1):302–310. https://doi.org/10.1148/radiol.2017161495
- Daniels J, Middleton LJ, Cheed V, et al. Uterine artery embolization or myomectomy for women with uterine fibroids: four-year follow-up of a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol X. 2022;13:100139. https://doi.org/10.1016/j.eurox.2021.100139